Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. is a biopharmaceutical enterprise focused on researching, developing, and commercializing therapeutic treatments. The company concentrates its operational endeavors on pharmaceutical solutions designed to address oncologic indications and critical viral conditions. Its development initiatives feature innovative proprietary candidates, including targeted antisense oligodeoxynucleotide therapies addressing transforming growth factor-beta and specialized synthetic formulations intended for diverse clinical applications across medicine.

The organization maintains its principal executive headquarters in Agoura Hills, California, with administrative facilities located at 29397 Agoura Road. Operating primarily within the United States regulatory and commercial framework, the company conducts its corporate leadership, governance, and development management directly from this location. Executive administration and development programs are centrally coordinated through this single primary domestic facility to oversee ongoing strategic activities.

Summary of the business section of Oncotelic Therapeutics's latest annual report, written by StockData.

“We had twenty-six full-time employees, four part-time employees and 10 consultants as of December 31, 2024; and all the employees and consultants were compensated by the JV during the years ended December 31, 2024 and 2023, respectively.”